

Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016

March 07, 2016

LAVAL, Quebec, March 7, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it plans to host a conference call and live webcast on March 15, 2016 to discuss preliminary fourth quarter 2015 financial results and update 2016 financial guidance.

"We are looking forward to providing Valeant shareholders with an update on the company's progress," stated J. Michael Pearson, chief executive officer. "February 29th was my first day back to work following a two month medical absence. Now that I have returned, I have been working diligently to review the business so that I can share our latest performance and outlook with shareholders."

Conference Call Details:

Date	Tuesday, March 15, 2016
Time	8:00 a.m. ET
Webcast	http://ir.valeant.com/events-and-presentations
Participant Event Dial-in	(877) 295-5743 (North America)
	(973) 200-3961 (International)
Participant Passcode	66610318
Replay Dial-in	(855) 859-2056 (North America)
	(404) 537-3406 (International)
Replay Passcode	66610318 (Replay available until 03/22/2016)

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding Valeant's financial reporting and future prospects. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Elif McDonald
905-695-7607
elif.mcdonald@valeant.com



Logo -

<http://photos.prnewswire.com/prnh/20101025/LA87217LOGO>

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-hold-conference-call-on-march-15-2016-300231520.html>

SOURCE Valeant Pharmaceuticals International, Inc.

Investor Inquiries

ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)



LEGAL NOTICE

PRIVACY POLICY

EMAIL ALERTS

EMAIL PAGE

RSS FEED

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION

